US 11,939,377 B2
Affinity matured CD22-specific monoclonal antibody and uses thereof
Dimiter S. Dimitrov, Pittsburgh, PA (US); Zhongyu Zhu, Frederick, MD (US); Sneha Ramakrishna, Bethesda, MD (US); and Terry J. Fry, Aurora, CO (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Appl. No. 17/259,334
Filed by The U.S.A., as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
PCT Filed Jul. 11, 2019, PCT No. PCT/US2019/041401
§ 371(c)(1), (2) Date Jan. 11, 2021,
PCT Pub. No. WO2020/014482, PCT Pub. Date Jan. 16, 2020.
Claims priority of provisional application 62/697,185, filed on Jul. 12, 2018.
Prior Publication US 2021/0324074 A1, Oct. 21, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 31/365 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); C07K 14/705 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 31/365 (2013.01); A61K 35/17 (2013.01); A61K 47/6803 (2017.08); A61K 47/6851 (2017.08); C07K 14/705 (2013.01); G01N 33/574 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2317/94 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01)] 35 Claims
 
1. A monoclonal antibody that binds CD22, or an antigen-binding fragment thereof, comprising a variable heavy (VH) domain and a variable light (VL) domain, wherein:
the VH domain comprises the complementarity determining region (CDR) sequences of SEQ ID NO: 4; and
the VL domain comprises the CDR sequences of SEQ ID NO: 5.